AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03389412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).
Study NCT03389412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conditional alarm
Description: Eight weeks of treatment.
Study NCT03389412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conditional alarm
Description: Eight weeks of treatment.
Study NCT04081402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HU-014
Description: Hutox Inj(Clostridium botulinum type A)
Study NCT04081402 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox Inj
Description: Botox Inj(Clostridium botulinum type A)
Study NCT01835288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV
Study NCT01835288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02148198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NWT-03, an egg-white protein hydrolysate
Description: For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
Study NCT02158195 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood samples
Study NCT01944254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac output measurement at random to respiration
Description: Cardiac output measurement obtained by pulmonary artery catheter thermodilution technique (PAC TD)
Study NCT01944254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac output measurement synchronised at start of expiration
Description: Cardiac output measurement obtained by PAC TD
Study NCT01944254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac output measurement timed to instructed exhalation
Description: Cardiac output measurement obtained by PAC TD
Study NCT00676091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
Study NCT00676091 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-Valent Pneumococcal Conjugate Vaccine (7vPnc)
Study NCT04646733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Diet Group
Description: The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet. This diet has 4 phases, two of weight loss until reaching the ideal weight (attack and cruise) and two of maintenance (consolidation and stabilization). During the first 2 phases, it allows 100 foods (28 vegetables). The first phase lasts 3-10 days and 72 high-protein, low-fat foods are allowed. In the second phase, there are alternate days between consuming the low glycemic index vegetables plus protein and the next day with just protein. The first two phases are ad libitum. Phase 3 (consolidation) aims to avoid rebound and begins the introduction of complex carbohydrates and legumes in individual servings. In phase 4 (stabilization), the subject returns to a free diet. However, three basic rules are introduced: protein one day a week, the exercise of at least 20 min/day (optional) and consumption of 3 tablespoons of oat bran/day.
Study NCT04646733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No High Protein Diet Group
Description: No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water. Beverage contained 1.6 g of betaG per portion according to FDA recommendations corresponding to 50 % of betaG required per day. Weekly bags containing oat mixture were provided on day 0 and in the third week of the trial. No additional instructions about diet, exercise program or pharmacological treatment was implemented.
Study NCT01767350 — intervention group
Intervention type: PROCEDURE
Intervention: Blood withdrawal for DNA
Description: Single withdrawal of 8 ml whole blood for DNA analysis, during a standard blood collection as part of standard clinical follow up.
Study NCT02213146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone human insulin
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study NCT02213146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioChaperone human insulin
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study NCT02213146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huminsulin® Normal
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study NCT02213146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huminsulin® Normal
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study NCT02213146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog®
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study NCT01880879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: helios stent
Description: the group with helios stent implanted
Study NCT02213146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study NCT02071043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3
Study NCT02824315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
Study NCT02824315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
Study NCT02824315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
Study NCT02071043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
Study NCT03293914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Redesign
Description: Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive approximately 8 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the intervention protocol.
Study NCT00589875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN-2409
Description: Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.
Study NCT00589875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3
Study NCT00589875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.
Study NCT00589875 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.
Study NCT01736475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Description: Pharmacokinetic (PK) evaluation of ADVATE
Study NCT01736475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Pharmacokinetic (PK) evaluation of BAX 855
Study NCT01736475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Prophylaxis treatment
Study NCT01736475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: On-demand treatment
Study NCT02408887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Thyroidectomy (TT)
Description: Total removal of thyroid
Study NCT02408887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic central neck lymph node dissection (pCND)
Description: Lymph node dissection
Study NCT00579462 — intervention group
Intervention type: OTHER
Intervention: Blood and Tissue studies
Description: Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
Study NCT03881644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imigran
Description: All patients will undergo this intervention on one of two study days
Study NCT03881644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: All patients will undergo this intervention on one of two study days
Study NCT03881644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pituitary adenylate cyclase-activating peptide-38
Description: All patients will undergo this intervention on both study days
Study NCT03881644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pituitary adenylate cyclase-activating peptide-38
Description: All patients will undergo this intervention on both study days
Study NCT02148198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
Study NCT02148198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
Study NCT01640223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom7
Description: patients will wear 2 Dexcom sensors 3 days before hospitalization.
Study NCT03943940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MNC and UC-MSC
Description: Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.~UC-MSC: 1-2 x 10\^6 cells/kg
Study NCT02289911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic training in the FAST
Description: Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
Study NCT02870517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxing Music
Description: Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have \<60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
Study NCT02870517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Music
Description: The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
Study NCT02032758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Single oral dose of 10 mg propranolol
Study NCT02032758 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Opal Device
Description: The Opal Device (APDM, Inc.) will be used to measure wrist movement.
Study NCT02032758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opal Device
Description: The Opal Device (APDM, Inc.) will be used to measure wrist movement.
Study NCT02032758 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Science and Motion PuttLab (SAM)
Description: The SAM will be used to study putter stroke movement and ball movement.
Study NCT02032758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Science and Motion PuttLab (SAM)
Description: The SAM will be used to study putter stroke movement and ball movement.
Study NCT02032758 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Surface Electromyography EMG
Description: The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
Study NCT02032758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface Electromyography EMG
Description: The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
Study NCT02919202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.
Description: Topical application to exposed dentine on one occasion.
Study NCT02919202 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-etching Dentine Bonding Agent
Description: Topical application to exposed dentine on one occasion followed by light-curing procedure.
Study NCT01241188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Tb
Description: The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
Study NCT01241188 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 TU Tuberculin PPD RT 23 SSI
Description: The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
Study NCT02931513 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Study NCT02931513 — intervention group
Intervention type: DEVICE
Intervention: Fibroscan
Study NCT02931513 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Study NCT02931513 — intervention group
Intervention type: BIOLOGICAL
Intervention: Liver biopsy
Description: Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
Study NCT02074670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill gait training
Description: Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
Study NCT02214888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, low dose
Study NCT02214888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, high dose
Study NCT02214888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02214888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04157153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
Description: Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
Study NCT04102800 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Benralizumab
Description: subcutaneous injection
Study NCT04060888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab (approximately 6 mg/kg)
Description: Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.
Study NCT04060888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 milligram (mg)
Description: Participants will receive 90 mg ustekinumab via SC route.
Study NCT04060888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to ustekinumab IV or SC.
Study NCT01869036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caudal anesthesia
Description: Standard caudal anesthesia (Marcaine 2mg/kg)
Study NCT01869036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caudal anesthesia supplemented with morphine
Description: Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
Study NCT02360670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control imaging
Study NCT02360670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional multimodal imaging
Study NCT05749991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dryshield
Description: DryShield combines the tasks of high-suction evacuator, saliva ejector, bite block, tongue shield, and oral pathway protector in one easy-to-use device.~The DryShield solution® is a patented autoclavable isolation system (MA, USA)
Study NCT05749991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton roll isolation
Description: Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
Study NCT00840268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel
Study NCT00840268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxypropyl Guar Galactomannan Vehicle
Description: Inactive ingredients used as a placebo comparator
Study NCT04332536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise with and without Codeine
Description: This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
Study NCT04332536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with and without Codeine
Description: This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
Study NCT00946608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
Study NCT00946608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
Study NCT00946608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)
Study NCT01640223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom7
Description: patients will wear 2 Dexcom sensor one day before hospitalization
Study NCT01777100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
Study NCT03428360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
Description: The subjects in this study administered DBF themselves or with the help of a caregiver, (trained by the study site staff in study drug administration and documentation) in the same setting as they typically used the diazepam rectal gel or other rescue medication, without the presence of study staff.
Study NCT01414855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
Study NCT01800487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silymarin
Description: 140 mg three times a day for 4 weeks
Study NCT01800487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (silymarin) 1 tab three times a day for 4 weeks
Study NCT01616472 — intervention group
Intervention type: DRUG
Intervention: Cumulative corticosteroid exposure
Description: Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.